STOCK TITAN

Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences clinical trial
Rhea-AI Summary

Vaxcyte, Inc. (Nasdaq: PCVX) announced a webcast on October 24, 2022, at 8:00 a.m. Eastern Time to discuss topline results from its Phase 1/2 proof-of-concept study for VAX-24, a 24-valent pneumococcal conjugate vaccine. The study evaluates safety, tolerability, and immunogenicity in healthy adults aged 18-64. Vaxcyte aims to innovate vaccine development using the XpressCF™ platform, striving to combat invasive bacterial infections with high-fidelity vaccines. The results will inform next steps for VAX-24 and Vaxcyte's broader vaccine portfolio.

Positive
  • Vaxcyte is conducting a Phase 1/2 proof-of-concept study for VAX-24, indicating progression in its vaccine development.
  • The investigational vaccine addresses a significant health need in bacterial disease prevention.
  • Expected topline results may provide insights into the safety and efficacy of VAX-24.
Negative
  • None.

SAN CARLOS, Calif., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, October 24, 2022, at 8:00 a.m. Eastern Time to provide topline results from its Phase 1/2 proof-of-concept study evaluating the safety, tolerability and immunogenicity of VAX-24, the Company’s investigational 24-valent pneumococcal conjugate vaccine (PCV), in healthy adults aged 18-64.

Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. A live webcast of the conference call will also be available on the investor relations page of the Vaxcyte corporate website at www.vaxcyte.com. After the live webcast, the event will remain archived on the Vaxcyte website for 30 days.

About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-XP, a PCV with an expanded breadth of coverage of greater than 30 strains; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements related to the potential benefits of Vaxcyte’s vaccine candidates and Vaxcyte’s ability to efficiently create and deliver such high-fidelity vaccines; and other statements that are not historical fact. The words “believe,” “could,” “expect,” “may,” “potential,” “should,” “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Vaxcyte’s current expectations and actual results and timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, including, without limitation, risks related to Vaxcyte’s product development programs, including development timelines, success and timing of chemistry, manufacturing and controls and related manufacturing activities, potential delays or inability to obtain and maintain required regulatory approvals for its vaccine candidates, and the risks and uncertainties inherent with preclinical and clinical development processes; the success, cost and timing of all development activities and clinical trials; impacts of COVID-19; and sufficiency of cash and other funding to support Vaxcyte’s development programs and other operating expenses. These and other risks are described more fully in Vaxcyte’s filings with the Securities and Exchange Commission (SEC), including, without limitation, its Quarterly Report on Form 10-Q filed with the SEC on August 8, 2022 or in other documents Vaxcyte subsequently files with or furnishes to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date, and readers should not rely upon the information in this press release as current or accurate after its publication date. Vaxcyte undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations, except as required by applicable law.

Contacts:
Andrew Guggenhime, President and Chief Financial Officer
Vaxcyte, Inc.
650-837-0111
investors@vaxcyte.com

Janet Graesser, Vice President, Corporate Communications and Investor Relations
Vaxcyte, Inc.
917-685-8799
media@vaxcyte.com


FAQ

What is VAX-24 and its significance for Vaxcyte?

VAX-24 is Vaxcyte's investigational 24-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease.

When will Vaxcyte announce the results of the VAX-24 study?

Vaxcyte will announce the topline results from its Phase 1/2 study on October 24, 2022.

What are the main objectives of Vaxcyte's Phase 1/2 trial for VAX-24?

The trial evaluates the safety, tolerability, and immunogenicity of VAX-24 in healthy adults aged 18-64.

How does Vaxcyte's technology improve vaccine development?

Vaxcyte uses the XpressCF™ platform for high-fidelity vaccine production, enhancing efficiency and immunological benefits.

What is the market potential for Vaxcyte's vaccines?

Vaxcyte is targeting significant bacterial disease prevention needs, which could yield substantial market opportunities.

Vaxcyte, Inc.

NASDAQ:PCVX

PCVX Rankings

PCVX Latest News

PCVX Stock Data

10.70B
120.72M
0.49%
112.31%
7.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN CARLOS